

Type 2 diabetes in adults: management: Guideline Update

1 Background

The Diabetes Management guideline (NG28) was reviewed in 2016 as part of NICE's routine surveillance programme to decide whether the guideline requires an update.

2 Guideline Update

We are answering the following question:

- 1. In adults with Type 2 diabetes, what is the clinical effectiveness of SGLT-2 inhibitors on cardiovascular outcomes?
- 2a. In adults with Type 2 diabetes, what is the clinical effectiveness of GLP1 mimetics on cardiovascular outcomes?
- 2b. In adults with Type 2 diabetes, what are the differences between a). The assumptions used in the HE model that informed NG28 and b). The empirical evidence from RCTs?

3 Guideline Update process

The guideline update will be produced using a standing Committee. NICE are piloting the use of a standing Committee for guideline updates. More information about the process can be found here:

[Guideline Updates](#)

Committee meeting dates: 28 April 2017, 17 July 2017 and 13 October 2017

Consultation dates: 31 August – 28 September 2017

Expected publication date: 12 December 2017